Abstract
Despite newly available treatments for spinal muscular atrophy (SMA), novel circulating biomarkers are still critically necessary to track SMA progression and therapeutic response. To identify potential biomarkers, we performed whole-blood RNA sequencing analysis in SMA type 1 subjects under 1 year old and age-matched healthy controls. Our analysis revealed the Heat Shock Protein Family A Member 7 (HSPA7) as a novel candidate biomarker to track SMA progression early in life. Changes in circulating HSPA7 protein levels were associated with changes in circulating neurofilaments levels in SMA newborns and infants. Future studies will determine whether HSPA7 levels respond to molecular therapies.
Competing Interest Statement
EJE, CRRA and RZ report no conflict of interest. MP, WF, PC and JAH are employees of Biogen and hold stock/stock options in Biogen. JFS was employed at Biogen at the time the work was performed and holds stock/stock options in Biogen; he is now employed at Vertex Pharmaceuticals, Boston. KJS is on the scientific advisory board for Cure SMA and is a consultant for Biogen, Roche and AveXis. KJS receives clinical trial funding from AveXis and Biogen.
Funding Statement
CRRA received a fellowship from the MGH Executive Committee on Research. KJS received financial support from NIH NICHD R01HD054599, NIH NINDS R21NS108015, Biogen and Cure SMA.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
. Written informed consent and parental consent were obtained from all participants under Institutional Ethics Review Boards at the University of Utah (protocol 8751) and Massachusetts General Hospital (protocol 2016P000469).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflict of Interest Statement: EJE, CRRA and RZ report no conflict of interest. MP, WF, PC and JAH are employees of Biogen and hold stock/stock options in Biogen. JFS was employed at Biogen at the time the work was performed and holds stock/stock options in Biogen; he is now employed at Vertex Pharmaceuticals, Boston. KJS is on the scientific advisory board for Cure SMA and is a consultant for Biogen, Roche and AveXis. KJS receives clinical trial funding from AveXis and Biogen.
Data Availability
RNA sequence data were submitted to NCBI Gene Expression Omnibus (GEO) and will be released post-publication.
